Daryl Klein

Assistant Professor

Yale University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2025

To find novel therapeutic targets in triple negative breast cancer, we performed cell surface proteomic profiling of cell lines. We identified Nectin-2, a cell adhesion molecule and immune regulator, that is over expressed in ∼70% of breast cancers relative to non-cancerous tissues as a promising target for ADC development. Using a human phage display Fab (fragment antigen-binding) library, we developed a high-affinity Fab against human Nectin-2, which we reformatted into a human IgG1 antibody (IgG-F1). The novel IgG-F1 binds Nectin-2 with high affinity (KD = 1 nM) and undergoes rapid internalization upon engagement. We also mapped the binding sites of F1 on Nectin-2 by Cryogenic electron microscopy analysis. To evaluate the therapeutic potential of this antibody, we generated ADCs using cleavable linkers with 3 different cytotoxic payloads (DM1, DXd, MMAE). The MMAE conjugated IgG-F1 demonstrated the highest in vitrocytotoxicity across a panel of breast cancer cell lines (IC50 range 1.24 - 11.76 nM). In an MDA-MB-468 xenograft model, this ADC also induced dose-dependent tumor regression and fully suppressed tumor growth in vivo at 10 mg/kg weekly dosing. In summary, we describe a novel ADC targeting Nectin-2 which exhibits selective tumor binding, efficient internalization, and potent anti-tumor activity in preclinical breast cancer models – supporting further development of anti-Nectin-2 therapeutics for human cancer treatment. Citation Format: Yueyue Wang, Naing Lin Shan, Xiaolong Zhu, Tongqing Li, Jiawei Dai, Hengyi Li, Florine Collin, Weiwei Wang, TuKiet T. Lam, Haiying Zhan, Kim RM. Blenman, Daryl E. Klein, Lajos Pusztai. Development of a novel antibody drug conjugate (ADC) targeting Nectin-2 on the surface of breast cancers [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2025 Oct 22-26; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2025;24(10 Suppl):Abstract nr B030.

Year:

2025

Year:

2025

Sevenless, the Drosophila homologue of ROS1 (University of Rochester Sarcoma) (herein, dROS1) is a receptor tyrosine kinase (RTK) essential for the differentiation of Drosophila R7 photoreceptor cells. Activation of dROS1 is mediated by binding to the extracellular region (ECR) of the GPCR (G protein coupled receptor) BOSS (Bride Of Sevenless) on adjacent cells. Activation of dROS1 by BOSS leads to subsequent downstream signaling pathways including SOS (Son of Sevenless). However, the physical basis for how dROS1 interacts with BOSS has long remained unknown. Here we provide a cryo-EM structure of dROS1’s extracellular region, which mediates ligand binding. We show that the extracellular region of dROS1 adopts a folded-over conformation stabilized by an N-terminal domain comprised of two disulfide stapled helical hairpins. We further narrowed down the interacting binding epitopes on both dROS1 and BOSS using hydrogen-deuterium exchange mass spectrometry (HDX-MS). This includes beta-strands in dROS1’s third Fibronectin type III (FNIII) domain and a C-terminal peptide in BOSS’ ECR. Our mutagenesis studies, coupled with AlphaFold complex predictions, support a binding interaction mediated by a hydrophobic interaction and beta-strand augmentation between these regions. Our findings provide a fundamental understanding of the regulatory function of dROS1 and further provide mechanistic insight into the human ortholog and oncogene ROS1.

Year:

2025

Collaborators (2)

Yansheng Liu

Associate Professor (Secondary)

Yale University School of Medicine

UNITED STATES
View details

Steven Stayrook

Senior Research Scientist

Yale University

UNITED STATES
View details